Circulation: Cardiovascular Imaging

© 2021 The Authors. Circulation: Cardiovascular Imaging is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-CommercialNoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made. BACKGROUND: Our goal was to evaluate the ability of cardiovascular magnetic resonance for detecting and predicting cardiac dysfunction in patients receiving cancer therapy. Left ventricular ejection fraction, global and regional strain utilizing fast-strain-encoded, T1 and T2 mapping, and cardiac biomarkers (troponin and BNP [brain natriuretic peptide]) were analyzed.

[1]  S. Plein,et al.  Role of cardiovascular magnetic resonance imaging in cardio-oncology. , 2021, European heart journal cardiovascular Imaging.

[2]  Jennifer E Liu,et al.  Strain Imaging in Cardio-Oncology , 2020, JACC. CardioOncology.

[3]  M. Takeuchi,et al.  A review of current trends in three-dimensional analysis of left ventricular myocardial strain , 2020, Cardiovascular Ultrasound.

[4]  J. Zamorano,et al.  Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Paul Yip,et al.  Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy?: Impact of Temporal and Observer Variability. , 2019, JACC. Cardiovascular imaging.

[6]  Andreas Schuster,et al.  Comparison of feature tracking, fast‐SENC, and myocardial tagging for global and segmental left ventricular strain , 2019, ESC heart failure.

[7]  G. Armstrong,et al.  Proceedings From the Global Cardio-Oncology Summit , 2019, JACC. CardioOncology.

[8]  Lei Deng,et al.  A population-based study of cardiovascular disease mortality risk in US cancer patients. , 2019, European heart journal.

[9]  L. Køber,et al.  Impact of Multiple Myocardial Scars Detected by CMR in Patients Following STEMI. , 2019, JACC. Cardiovascular imaging.

[10]  Scott A. Prentice,et al.  Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial , 2019, The Lancet.

[11]  K. Bhaskaran,et al.  Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases , 2019, The Lancet.

[12]  Amit R. Patel,et al.  Strain‐encoded magnetic resonance: a method for the assessment of myocardial deformation , 2019, ESC heart failure.

[13]  Jennifer E Liu,et al.  Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction , 2019, Breast Cancer Research and Treatment.

[14]  Amit R. Patel,et al.  Reproducibility study on myocardial strain assessment using fast-SENC cardiac magnetic resonance imaging , 2018, Scientific Reports.

[15]  C. Rapezzi,et al.  Prodromal angina and risk of 2-year cardiac mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention , 2018, Medicine.

[16]  E. E. van der Wall,et al.  Cardio-oncology: an overview on outpatient management and future developments , 2018, Netherlands Heart Journal.

[17]  L. Køber,et al.  Impact of diagnostic ECG-to-wire delay in STEMI patients treated with primary PCI: a DANAMI-3 substudy. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[18]  H. Thiele,et al.  Impact of chronic total occlusion in a non-infarct-related coronary artery on myocardial injury assessed by cardiac magnetic resonance imaging and prognosis in ST-elevation myocardial infarction. , 2018, International journal of cardiology.

[19]  F. Cendes,et al.  Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease. , 2018, JACC. Cardiovascular imaging.

[20]  G. Schuler,et al.  Impact of multivessel coronary artery disease on reperfusion success in patients with ST-elevation myocardial infarction: A substudy of the AIDA STEMI trial , 2017, European heart journal. Acute cardiovascular care.

[21]  L. Køber,et al.  Myocardial Damage in Patients With Deferred Stenting After STEMI: A DANAMI-3-DEFER Substudy. , 2017, Journal of the American College of Cardiology.

[22]  Jens-Uwe Voigt,et al.  Intervendor Differences in the Accuracy of Detecting Regional Functional Abnormalities: A Report From the EACVI-ASE Strain Standardization Task Force. , 2017, JACC. Cardiovascular imaging.

[23]  C. Terkelsen,et al.  Effect of Ischemic Postconditioning During Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial , 2017, JAMA cardiology.

[24]  C. Cipolla,et al.  Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy , 2017, Expert review of molecular diagnostics.

[25]  L. Køber,et al.  Left Ventricular Hypertrophy Is Associated With Increased Infarct Size and Decreased Myocardial Salvage in Patients With ST‐Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention , 2017, Journal of the American Heart Association.

[26]  J. Georges,et al.  Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy for the prediction of subsequent cardiotoxicity. , 2016, Annales de cardiologie et d'angeiologie.

[27]  G. Lip,et al.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). , 2016, European heart journal.

[28]  Eike Nagel,et al.  T1 Mapping in Characterizing Myocardial Disease: A Comprehensive Review. , 2016, Circulation research.

[29]  J. Plana,et al.  The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study. , 2016, Journal of cardiac failure.

[30]  C. Terkelsen,et al.  Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial , 2016, The Lancet.

[31]  E. Ohman,et al.  Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. , 2016, Journal of the American College of Cardiology.

[32]  Morten Wang Fagerland,et al.  Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol , 2016, European heart journal.

[33]  L. Køber,et al.  Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial , 2015, The Lancet.

[34]  G. Curigliano,et al.  Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy , 2015, Circulation.

[35]  Sang-Wook Kim,et al.  Long-term effects of ischemic postconditioning on clinical outcomes: 1-year follow-up of the POST randomized trial. , 2015, American heart journal.

[36]  H. Bøtker,et al.  The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: Ischemic postconditioning or deferred stent implantation versus conventional primary angioplasty and complete revascularization versus treatment of culprit lesion only: Rationale and design , 2015, American heart journal.

[37]  M. Cerqueira,et al.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2014, European heart journal cardiovascular Imaging.

[38]  Holger Thiele,et al.  Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction. , 2014, Journal of the American College of Cardiology.

[39]  M. Kohli,et al.  Evaluation and management of patients with heart disease and cancer: cardio-oncology. , 2014, Mayo Clinic proceedings.

[40]  Paaladinesh Thavendiranathan,et al.  Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. , 2014, Journal of the American College of Cardiology.

[41]  S. Flamm,et al.  Cardiac MRI in the Assessment of Cardiac Injury and Toxicity From Cancer Chemotherapy: A Systematic Review , 2013, Circulation. Cardiovascular imaging.

[42]  V. Roger.  Epidemiology of Heart Failure , 2013, Circulation research.

[43]  W. Hundley,et al.  Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. , 2013, JACC. Cardiovascular imaging.

[44]  G. Krombach,et al.  Layer-specific strain-encoded MRI for the evaluation of left ventricular function and infarct transmurality in patients with chronic coronary artery disease. , 2013, International journal of cardiology.

[45]  H. Bøtker,et al.  Final infarct size measured by cardiovascular magnetic resonance in patients with ST elevation myocardial infarction predicts long-term clinical outcome: an observational study. , 2013, European heart journal cardiovascular Imaging.

[46]  C. Berry,et al.  Prognostic importance of myocardial infarct characteristics. , 2013, European heart journal cardiovascular Imaging.

[47]  C. Thomsen,et al.  Myocardial area at risk and salvage measured by T2-weighted cardiovascular magnetic resonance: Reproducibility and comparison of two T2-weighted protocols , 2011, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[48]  Jens-Uwe Voigt,et al.  Acute radiation effects on cardiac function detected by strain rate imaging in breast cancer patients. , 2011, International journal of radiation oncology, biology, physics.

[49]  F. Veglia,et al.  Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. , 2010, Journal of the American College of Cardiology.

[50]  D. Jassal,et al.  Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study , 2009, Breast Cancer Research and Treatment.

[51]  Hugo A. Katus,et al.  Strain-Encoded MRI for Evaluation of Left Ventricular Function and Transmurality in Acute Myocardial Infarction , 2009, Circulation. Cardiovascular imaging.

[52]  J. Schulz-Menger,et al.  The salvaged area at risk in reperfused acute myocardial infarction as visualized by cardiovascular magnetic resonance. , 2008, Journal of the American College of Cardiology.

[53]  M. Jessup,et al.  Stage B Heart Failure: Management of Asymptomatic Left Ventricular Systolic Dysfunction , 2006, Circulation.

[54]  Olga Bondarenko,et al.  Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. , 2005, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[55]  G. Martinelli,et al.  Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy , 2004, Circulation.

[56]  J. Schulz-Menger,et al.  Delayed Enhancement and T2-Weighted Cardiovascular Magnetic Resonance Imaging Differentiate Acute From Chronic Myocardial Infarction , 2004, Circulation.

[57]  O. Simonetti,et al.  Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. , 1999, Circulation.

[58]  M. Galvani,et al.  Prodromal angina limits infarct size. A role for ischemic preconditioning. , 1995, Circulation.

[59]  R. Kloner,et al.  Regional Ischemic 'Preconditioning' Protects Remote Virgin Myocardium From Subsequent Sustained Coronary Occlusion , 1993, Circulation.

[60]  P. Steinherz,et al.  Cardiac toxicity 4 to 20 years after completing anthracycline therapy. , 1991, JAMA.

[61]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[62]  R. Jennings,et al.  Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. , 1986, Circulation.

[63]  Jens-Uwe Voigt,et al.  Variability and Reproducibility of Segmental Longitudinal Strain Measurement: A Report From the EACVI-ASE Strain Standardization Task Force. , 2018, JACC. Cardiovascular imaging.

[64]  G. De Luca,et al.  Preinfarction angina does not affect infarct size in STEMI patients undergoing primary angioplasty. , 2013, Atherosclerosis.

[65]  B. Gersh,et al.  Angiographic Versus Functional Severity of Coronary Artery Stenoses in the FAME Study: Fractional Flow Reserve Versus Angiography in Multivessel Evaluation , 2011 .

[66]  L. Becker.  Myocardial Reperfusion Injury , 2004, Journal of Thrombosis and Thrombolysis.

[67]  G. Schuler,et al.  Effect of preinfarction angina pectoris on outcome in patients with acute myocardial infarction treated with primary angioplasty (results from the Myocardial Infarction Registry. , 2001, The American journal of cardiology.

[68]  C. Cannon,et al.  Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? , 1995, Circulation.